EP2248519A3 - Formes galéniques de film non mucoadhésifs - Google Patents
Formes galéniques de film non mucoadhésifs Download PDFInfo
- Publication number
- EP2248519A3 EP2248519A3 EP10007501A EP10007501A EP2248519A3 EP 2248519 A3 EP2248519 A3 EP 2248519A3 EP 10007501 A EP10007501 A EP 10007501A EP 10007501 A EP10007501 A EP 10007501A EP 2248519 A3 EP2248519 A3 EP 2248519A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- dosage forms
- film dosage
- mucoadhesive film
- methods
- mucoadhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 210000002200 mouth mucosa Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL10007501T PL2248519T3 (pl) | 2006-10-02 | 2007-10-02 | Niemukoadhezyjne postaci dawkowania w postaci filmu |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84896506P | 2006-10-02 | 2006-10-02 | |
EP07818659A EP2076251A2 (fr) | 2006-10-02 | 2007-10-02 | Formes pharmaceutiques à base de film non muco-adhésif |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07818659.0 Division | 2007-10-02 | ||
EP07818659A Division EP2076251A2 (fr) | 2006-10-02 | 2007-10-02 | Formes pharmaceutiques à base de film non muco-adhésif |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2248519A2 EP2248519A2 (fr) | 2010-11-10 |
EP2248519A3 true EP2248519A3 (fr) | 2011-12-14 |
EP2248519B1 EP2248519B1 (fr) | 2017-12-06 |
Family
ID=38882216
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07818659A Withdrawn EP2076251A2 (fr) | 2006-10-02 | 2007-10-02 | Formes pharmaceutiques à base de film non muco-adhésif |
EP10007501.9A Active EP2248519B1 (fr) | 2006-10-02 | 2007-10-02 | Formes galéniques de film non mucoadhésifs |
EP11178296.7A Withdrawn EP2444072A3 (fr) | 2006-10-02 | 2007-10-02 | Formes galéniques de film non mucoadhésifs |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07818659A Withdrawn EP2076251A2 (fr) | 2006-10-02 | 2007-10-02 | Formes pharmaceutiques à base de film non muco-adhésif |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11178296.7A Withdrawn EP2444072A3 (fr) | 2006-10-02 | 2007-10-02 | Formes galéniques de film non mucoadhésifs |
Country Status (15)
Country | Link |
---|---|
US (3) | US8580830B2 (fr) |
EP (3) | EP2076251A2 (fr) |
KR (1) | KR101448050B1 (fr) |
CN (2) | CN101626756A (fr) |
AU (1) | AU2007304425B2 (fr) |
BR (1) | BRPI0719840A2 (fr) |
CA (1) | CA2664986C (fr) |
DE (1) | DE202007019476U1 (fr) |
DK (1) | DK2248519T3 (fr) |
ES (1) | ES2652592T3 (fr) |
HU (1) | HUE038022T4 (fr) |
MX (1) | MX2009003372A (fr) |
NZ (1) | NZ575900A (fr) |
PL (1) | PL2248519T3 (fr) |
WO (1) | WO2008040534A2 (fr) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
CN102846585A (zh) | 2006-03-28 | 2013-01-02 | 杰佛林制药公司 | 低剂量的双氯芬酸和β-环糊精的制剂 |
MX2009000745A (es) | 2006-07-21 | 2009-04-16 | Biodelivery Sciences Int Inc | Dispositivos de suministro transmucosa con admision mejorada. |
EP1897543A1 (fr) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Gaufre de buprénorphine pour la thérapie de substitution |
US8580830B2 (en) * | 2006-10-02 | 2013-11-12 | Labtec Gmbh | Non-mucoadhesive film dosage forms |
ES2562878T3 (es) | 2007-05-25 | 2016-03-08 | Indivior Uk Limited | Formulaciones de liberación sostenida de compuestos de risperidona |
GR20070100405A (el) * | 2007-06-26 | 2009-01-20 | Genepharm �.�. | Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων |
EP2674150A1 (fr) * | 2009-01-28 | 2013-12-18 | Labtec GmbH | Préparation pharmaceutique ayant une stabilité dýagent actif améliorée |
US20100297232A1 (en) * | 2009-05-19 | 2010-11-25 | Monosol Rx, Llc | Ondansetron film compositions |
US20110097401A1 (en) | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
EP2442650B1 (fr) | 2009-06-12 | 2015-08-26 | Cynapsus Therapeutics Inc. | Apomorphine sublinguale |
KR101074271B1 (ko) * | 2009-06-25 | 2011-10-17 | (주)차바이오앤디오스텍 | 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 |
US8475832B2 (en) * | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
UY32836A (es) | 2009-08-12 | 2011-03-31 | Bayer Schering Pharma Ag | Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato |
EP2467126A1 (fr) | 2009-08-19 | 2012-06-27 | Bayer Pharma Aktiengesellschaft | Systèmes d'administration de médicaments (cachets) destinés à une utilisation pédiatrique |
AU2010343147A1 (en) * | 2009-12-28 | 2012-07-19 | Monosol Rx, Llc | Orally administrable film dosage forms containing ondansetron |
CN103025321A (zh) * | 2010-03-23 | 2013-04-03 | 生物联合制药公司 | 快速溶解的药物释放系统 |
EP2377526A1 (fr) | 2010-03-23 | 2011-10-19 | BioAlliance Pharma | Systèmes d'administration de médicaments à dissolution rapide |
EP2374448A1 (fr) | 2010-04-06 | 2011-10-12 | Labtec GmbH | Formulation de film oral |
GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
NZ605888A (en) * | 2010-08-04 | 2014-08-29 | Gruenenthal Gmbh | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain |
US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
DE102010049708A1 (de) | 2010-10-28 | 2012-05-03 | Hexal Ag | Orale pharmazeutische Filmformulierung für bitter schmeckende Arzneistoffe |
AU2011343429B2 (en) | 2010-12-16 | 2016-10-20 | Sunovion Pharmaceuticals Inc. | Sublingual films |
MX349803B (es) * | 2011-02-11 | 2017-08-14 | Ctc Bio Inc | Preparación farmacéutica de película que contiene sildenafil en su forma de base libre y método para producir dicha preparación. |
EP2486913A1 (fr) * | 2011-02-14 | 2012-08-15 | Labtec GmbH | Formulation de film oral à désintégration rapide pour olanzapine |
KR101318059B1 (ko) * | 2011-07-01 | 2013-10-15 | 광동제약 주식회사 | 로페라마이드와 베타-시클로덱스트린 포접물을 함유하는 가식성 필름제제 |
KR101971620B1 (ko) | 2011-10-31 | 2019-04-24 | 삼성전자주식회사 | 샘플링 방법, 이를 수행하는 장치, 프로브, 수신 빔포밍 장치 및 의료영상시스템 |
WO2013085276A1 (fr) * | 2011-12-08 | 2013-06-13 | 에스케이케미칼 주식회사 | Film pour administration orale contenant du mirodénafil ou l'un de ses sels pharmaceutiquement acceptables |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
JP5941558B2 (ja) * | 2012-02-28 | 2016-06-29 | 株式会社ソウル製薬Seoul Pharma. Co., Ltd. | シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム |
KR101440808B1 (ko) * | 2012-10-22 | 2014-11-04 | 주식회사 서울제약 | 실데나필 또는 이의 약제학적으로 허용되는 염을 고함량으로 포함하는 속용필름 |
CN102920683B (zh) * | 2012-06-11 | 2013-08-14 | 江苏豪森药业股份有限公司 | 奥氮平口腔速溶膜 |
US20140073678A1 (en) * | 2012-09-12 | 2014-03-13 | Monosol Rx, Llc | Anti-pain and anti-nausea and/or vomiting combinatorial compositions |
CN102824333B (zh) * | 2012-09-26 | 2014-05-14 | 苏州大学 | 一种口腔速溶膜剂及其制备方法 |
CN102846581A (zh) * | 2012-09-28 | 2013-01-02 | 天津市聚星康华医药科技有限公司 | 一种盐酸氨溴索口腔速溶膜及其制备方法 |
US20140275194A1 (en) * | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Films and drug delivery systems for rizatriptan |
WO2014182138A1 (fr) * | 2013-05-10 | 2014-11-13 | 주식회사 씨티씨바이오 | Préparation de film contenant une base exempte de donépézil et procédé de production correspondant |
KR101553207B1 (ko) * | 2013-08-02 | 2015-09-17 | 주식회사 서울제약 | 도네페질 또는 그의 약제학적으로 허용되는 염을 함유한 구강붕해필름 제제 및 그의 제조방법 |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
NZ727834A (en) * | 2014-06-24 | 2020-08-28 | Taho Pharmaceuticals Ltd | Fast acting orally disintegrating film |
US10226450B2 (en) | 2014-09-25 | 2019-03-12 | Shilpa Medicare Limited | Pharmaceutical film composition |
WO2016172095A1 (fr) | 2015-04-21 | 2016-10-27 | Cynapsus Therapeutics, Inc. | Méthodes de traitement de la maladie de parkinson par l'administration d'apomorphine à une muqueuse orale |
CN105055378B (zh) * | 2015-08-19 | 2017-09-12 | 山东省药学科学院 | 一种盐酸美克洛嗪的口腔速释膜剂及其制备方法 |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
CA3022840A1 (fr) | 2016-05-05 | 2017-11-09 | Aquestive Therapeutics, Inc. | Compositions d'epinephrine a administration amelioree |
EP3299010B1 (fr) | 2016-09-21 | 2022-11-09 | LTS Lohmann Therapie-Systeme AG | Forme pharmaceutique orale |
JP7182639B2 (ja) | 2018-03-01 | 2022-12-02 | エルテーエス ローマン テラピー-ジステーメ アーゲー | テオブロミンフリーのココアを含有する経口剤形 |
CN108743567A (zh) * | 2018-08-24 | 2018-11-06 | 北京太阳升高科医药研究股份有限公司 | 氢溴酸加兰他敏口溶膜剂及其制备方法 |
CN108785289A (zh) * | 2018-09-06 | 2018-11-13 | 北京太阳升高科医药研究股份有限公司 | 盐酸那拉曲坦口溶膜剂及其制备方法 |
US11179331B1 (en) | 2020-04-21 | 2021-11-23 | Cure Pharmaceutcai Holding Corp | Oral soluble film containing sildenafil citrate |
KR102413426B1 (ko) * | 2020-12-21 | 2022-06-29 | 주식회사 씨엠지제약 | 나라트립탄을 포함하는 구강용해 필름 제형 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005039543A1 (fr) * | 2003-10-27 | 2005-05-06 | Pharmafilm S.R.L. | Films auto-sustentateurs pour utilisation pharmaceutique et alimentaire |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4136162A (en) * | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
DE4018247A1 (de) | 1990-06-07 | 1991-12-12 | Lohmann Therapie Syst Lts | Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen |
AU7568394A (en) * | 1993-08-19 | 1995-03-14 | Cygnus Therapeutic Systems | Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity |
US5898211A (en) | 1996-04-30 | 1999-04-27 | Cutting Edge Optronics, Inc. | Laser diode package with heat sink |
US5800832A (en) | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
US6596298B2 (en) * | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
US6520329B1 (en) | 1998-12-09 | 2003-02-18 | Lts Lohmann Thapie-Systeme Ag | Packaging for planiform objects/products |
US6750921B1 (en) | 1999-06-30 | 2004-06-15 | Thomson Licensing S.A. | Projection video display with photo transistor sensors |
US20050118637A9 (en) * | 2000-01-07 | 2005-06-02 | Levinson Douglas A. | Method and system for planning, performing, and assessing high-throughput screening of multicomponent chemical compositions and solid forms of compounds |
DE10008165A1 (de) | 2000-02-23 | 2001-08-30 | Lohmann Therapie Syst Lts | Verpackung flächenförmiger Gegenstände mit verbesserter Aufreisseigenschaft |
US7067116B1 (en) | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
DE10102818A1 (de) | 2001-01-23 | 2002-08-08 | Lohmann Therapie Syst Lts | Primärverpackungseinheit für mehrere vereinzelte Filmplättchen als Darreichungsformen |
US7666337B2 (en) * | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
DE10159746B4 (de) * | 2001-12-05 | 2006-05-18 | Lts Lohmann Therapie-Systeme Ag | Spendevorrichtung für flächenförmige Darreichungsformen |
CN1665803A (zh) | 2002-04-30 | 2005-09-07 | 特瓦药厂有限公司 | 新晶形的昂丹司琼及其制备方法、含有该新晶形的药物组合物以及用其治疗恶心的方法 |
CN100396332C (zh) | 2002-05-16 | 2008-06-25 | 救急药品工业株式会社 | 速溶性膜剂 |
GB0217382D0 (en) | 2002-07-26 | 2002-09-04 | Pfizer Ltd | Process for making orally consumable dosage forms |
EP2716284A3 (fr) | 2003-05-28 | 2014-11-05 | MonoSol RX LLC | Films à base d'oxyde de polyéthylène et systèmes d'administration de médicament fabriqués à partir de ceux-ci |
CN1565429A (zh) | 2003-07-09 | 2005-01-19 | 吴缨 | 口腔速溶薄膜制剂及制备方法 |
US20050175689A1 (en) * | 2003-10-27 | 2005-08-11 | Yamanouchi Pharmaceutical Co., Ltd. | Coated fine particles containing drug for intrabuccally fast disintegrating tablet |
EP1776089A2 (fr) * | 2003-12-31 | 2007-04-25 | Actavis Group hf | Formulations de donepezil |
ES2238001B1 (es) | 2004-01-21 | 2006-11-01 | Vita Cientifica, S.L. | Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos. |
DE102004056576A1 (de) | 2004-11-23 | 2006-05-24 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Rapidcard |
EP1681048A1 (fr) | 2005-01-14 | 2006-07-19 | Krka Tovarna Zdravil, D.D., Novo Mesto | Composition à désintégration orale à base d'olanzépine ou de donepézil |
DE102005033942A1 (de) | 2005-07-20 | 2007-02-22 | Hexal Ag | Nicht-ausspuckbarer, oraler, schnell-zerfallender Film für Antiemetikum oder Antimigränemittel |
IL175338A0 (en) * | 2006-05-01 | 2006-09-05 | Biota Ltd | Orally administrable films and preparation thereof |
US8580830B2 (en) * | 2006-10-02 | 2013-11-12 | Labtec Gmbh | Non-mucoadhesive film dosage forms |
-
2007
- 2007-10-02 US US12/443,414 patent/US8580830B2/en active Active
- 2007-10-02 NZ NZ575900A patent/NZ575900A/en unknown
- 2007-10-02 ES ES10007501.9T patent/ES2652592T3/es active Active
- 2007-10-02 CN CN200780044412A patent/CN101626756A/zh active Pending
- 2007-10-02 EP EP07818659A patent/EP2076251A2/fr not_active Withdrawn
- 2007-10-02 HU HUE10007501A patent/HUE038022T4/hu unknown
- 2007-10-02 BR BRPI0719840-0A2A patent/BRPI0719840A2/pt not_active IP Right Cessation
- 2007-10-02 EP EP10007501.9A patent/EP2248519B1/fr active Active
- 2007-10-02 DK DK10007501.9T patent/DK2248519T3/en active
- 2007-10-02 AU AU2007304425A patent/AU2007304425B2/en active Active
- 2007-10-02 PL PL10007501T patent/PL2248519T3/pl unknown
- 2007-10-02 MX MX2009003372A patent/MX2009003372A/es not_active Application Discontinuation
- 2007-10-02 CA CA2664986A patent/CA2664986C/fr active Active
- 2007-10-02 CN CN201510501616.1A patent/CN105168186A/zh active Pending
- 2007-10-02 EP EP11178296.7A patent/EP2444072A3/fr not_active Withdrawn
- 2007-10-02 WO PCT/EP2007/008579 patent/WO2008040534A2/fr active Application Filing
- 2007-10-02 KR KR1020097007210A patent/KR101448050B1/ko active IP Right Grant
- 2007-10-02 DE DE202007019476U patent/DE202007019476U1/de not_active Expired - Lifetime
-
2013
- 2013-10-11 US US14/052,034 patent/US9682037B2/en active Active
-
2015
- 2015-03-16 US US14/658,907 patent/US20160022574A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005039543A1 (fr) * | 2003-10-27 | 2005-05-06 | Pharmafilm S.R.L. | Films auto-sustentateurs pour utilisation pharmaceutique et alimentaire |
Also Published As
Publication number | Publication date |
---|---|
EP2248519A2 (fr) | 2010-11-10 |
DE202007019476U1 (de) | 2013-01-25 |
HUE038022T4 (hu) | 2023-02-28 |
US9682037B2 (en) | 2017-06-20 |
AU2007304425A1 (en) | 2008-04-10 |
DK2248519T3 (en) | 2018-01-02 |
CN105168186A (zh) | 2015-12-23 |
AU2007304425B2 (en) | 2013-12-05 |
EP2444072A3 (fr) | 2014-05-07 |
US20100173940A1 (en) | 2010-07-08 |
MX2009003372A (es) | 2009-09-24 |
US20140179653A1 (en) | 2014-06-26 |
US8580830B2 (en) | 2013-11-12 |
HUE038022T2 (hu) | 2018-10-29 |
CN101626756A (zh) | 2010-01-13 |
KR20090080037A (ko) | 2009-07-23 |
CA2664986C (fr) | 2015-09-22 |
EP2076251A2 (fr) | 2009-07-08 |
EP2248519B1 (fr) | 2017-12-06 |
KR101448050B1 (ko) | 2014-10-14 |
EP2444072A2 (fr) | 2012-04-25 |
US20160022574A1 (en) | 2016-01-28 |
CA2664986A1 (fr) | 2008-04-10 |
WO2008040534A3 (fr) | 2009-01-22 |
NZ575900A (en) | 2012-04-27 |
WO2008040534A2 (fr) | 2008-04-10 |
ES2652592T3 (es) | 2018-02-05 |
BRPI0719840A2 (pt) | 2014-11-25 |
PL2248519T3 (pl) | 2018-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2248519A3 (fr) | Formes galéniques de film non mucoadhésifs | |
MX2009002196A (es) | Oblea de buprenorfina para terapia de sustitucion de farmacos. | |
MX2011013902A (es) | Tratamiento de esclerosis multiple con laquinimod. | |
EP3738587A3 (fr) | Formule de dosage pour insertion dans la bouche | |
WO2007012022A3 (fr) | Forme posologique unitaire renfermant un melange d'ibuprofene et de famotidine | |
FI3782612T3 (fi) | Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi | |
EA200870325A1 (ru) | Лекарственные формы для введения комбинаций лекарственных средств | |
WO2008085765A3 (fr) | Formes dosifiées de petit volume de médicament contenant du sufentanil s'administrant par voie trans-muqueuse orale pour le traitement de la douleur | |
JP2009536147A5 (fr) | ||
ATE543489T1 (de) | Orale dosierformen mit progesteron und verwendungs- und herstellungsverfahren dafür | |
CA2683786C (fr) | Utilisation du tapentadol dans le traitement de la douleur et avec une incidence reduite d'effets secondaires induits par le tapentadol | |
IL203747A (en) | Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it | |
WO2007070677A3 (fr) | Compositions pharmaceutiques et procedes de traitement ou de prevention d'une maladie associee a l'oxalate | |
WO2008027854A3 (fr) | Compositions pharmaceutiques à hormone de croissance humaine pour délivrance par voie orale | |
UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина | |
WO2008011426A3 (fr) | Procédés et médicaments destinés à l'administration d'ibuprofène | |
ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
WO2011151722A3 (fr) | Méthodes et compositions de traitement pharmaceutique par voie orale | |
CO6270217A2 (es) | Formulaciones galenicas de alisquireno y valsartan | |
NZ612063A (en) | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration | |
WO2007133796A3 (fr) | Procédés et compositions de traitement de l'apnée du sommeil | |
EP1778209B8 (fr) | Methodes et compositions d'administration orale de fts | |
JP2011500589A5 (fr) | ||
WO2006079910A3 (fr) | Composition pour traitement des lesions de la cavite buccale | |
MA31227B1 (fr) | Composition pharmaceutique renfermant du phloroglucinol et du paracetamol. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2076251 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GALFETTI, PAOLO Inventor name: BREITENBACH, ARMIN Inventor name: LEHRKE, INGO Inventor name: LEICHS, CHRISTIAN |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LEHRKE, INGO Inventor name: BREITENBACH, ARMIN Inventor name: LEICHS, CHRISTIAN Inventor name: GALFETTI, PAOLO |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/70 20060101AFI20111104BHEP Ipc: A61K 31/4178 20060101ALI20111104BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1150544 Country of ref document: HK |
|
17P | Request for examination filed |
Effective date: 20120613 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LABTEC GMBH |
|
17Q | First examination report despatched |
Effective date: 20131003 |
|
111L | Licence recorded |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC MT NL PL PT RO SE SI SK TR Free format text: EXCLUSIVE LICENSE Name of requester: APR APPLIED PHARMA RESEARCH S.A., CH Effective date: 20120920 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: TESA LABTEC GMBH |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: APR APPLIED PHARMA RESEARCH S.A. |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20170523 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LEICHS, CHRISTIAN Inventor name: LEHRKE, INGO Inventor name: GALFETTI, PAOLO Inventor name: BREITENBACH, ARMIN |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
111L | Licence recorded |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC MT NL PL PT RO SE SI SK TR Free format text: EXCLUSIVE LICENSE Name of requester: APR APPLIED PHARMA RESEARCH S.A., CH Effective date: 20120920 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2076251 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 951741 Country of ref document: AT Kind code of ref document: T Effective date: 20171215 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20171221 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007053326 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2652592 Country of ref document: ES Kind code of ref document: T3 Effective date: 20180205 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 26096 Country of ref document: SK |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1150544 Country of ref document: HK |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171206 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 951741 Country of ref document: AT Kind code of ref document: T Effective date: 20171206 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171206 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180306 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180307 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171206 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171206 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602007053326 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E038022 Country of ref document: HU |
|
26N | No opposition filed |
Effective date: 20180907 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171206 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171206 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181002 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181002 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171206 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171206 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171206 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180406 |
|
REG | Reference to a national code |
Ref country code: FI Ref legal event code: PCE Owner name: SPEPHARM AG |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20201224 AND 20201230 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: PD Owner name: SPEPHARM AG; CH Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: APR APPLIED PHARMA RESEARCH S.A. Effective date: 20210118 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: PD Owner name: SPEPHARM AG; CH Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION; FORMER OWNER NAME: APR APPLIED PHARMA RESEARCH S.A. Effective date: 20201216 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602007053326 Country of ref document: DE Representative=s name: KOENIG SZYNKA TILMANN VON RENESSE PATENTANWAEL, DE Ref country code: DE Ref legal event code: R081 Ref document number: 602007053326 Country of ref document: DE Owner name: SPEPHARM AG, CH Free format text: FORMER OWNER: APR APPLIED PHARMA RESEARCH S.A., BALERNA, CH |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: SPEPHARM AG Effective date: 20210216 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: PC4A Ref document number: E 26096 Country of ref document: SK Owner name: SPEPHARM AG, LUZERN, CH Free format text: FORMER OWNER: APR APPLIED PHARMA RESEARCH S.A., BALERNA, CH Effective date: 20210211 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: GB9C Owner name: SPEPHARM AG, CH Free format text: FORMER OWNER(S): APR APPLIED PHARMA RESEARCH S.A., CH Ref country code: HU Ref legal event code: FH1C Free format text: FORMER REPRESENTATIVE(S): ARINOVA SZABADALMI ES VEDJEGY IRODA, HU Representative=s name: GOEDOELLE, KEKES, MESZAROS & SZABO SZABADALMI ES VEDJEGY IRODA, HU |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4B Ref document number: E038022 Country of ref document: HU |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230507 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: RO Payment date: 20230918 Year of fee payment: 17 Ref country code: NL Payment date: 20230915 Year of fee payment: 17 Ref country code: IT Payment date: 20230913 Year of fee payment: 17 Ref country code: IE Payment date: 20230912 Year of fee payment: 17 Ref country code: GB Payment date: 20230831 Year of fee payment: 17 Ref country code: CZ Payment date: 20230919 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SK Payment date: 20230912 Year of fee payment: 17 Ref country code: SE Payment date: 20230912 Year of fee payment: 17 Ref country code: PL Payment date: 20230908 Year of fee payment: 17 Ref country code: FR Payment date: 20230921 Year of fee payment: 17 Ref country code: BE Payment date: 20230918 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20231109 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: HU Payment date: 20230926 Year of fee payment: 17 Ref country code: FI Payment date: 20231011 Year of fee payment: 17 Ref country code: DK Payment date: 20231016 Year of fee payment: 17 Ref country code: DE Payment date: 20230906 Year of fee payment: 17 |